BR0012129A - Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os - Google Patents
Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-osInfo
- Publication number
- BR0012129A BR0012129A BR0012129-0A BR0012129A BR0012129A BR 0012129 A BR0012129 A BR 0012129A BR 0012129 A BR0012129 A BR 0012129A BR 0012129 A BR0012129 A BR 0012129A
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- compounds
- cell
- preparation
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Patente de Invenção: "DERIVADOS DE NAFTIRIDINA, PROCESSOS PARA SUA PREPARAçãO, SEU USO E COMPOSIçõES FARMACêUTICAS COMPREENDENDO-OS". A presente invenção diz respeito aos compostos da fórmula I, em que B, G, Z, X, Y, r, s e t têm os significados indicados nas reivindicações, seus sais fisiologicamente toleráveis e seus pró medicamentos. Os compostos da fórmula I são compostos farmacologicamente ativos valiosos. Eles são antagonistas de receptor de vitronectina e inibidores de adesão celular e são adequados para a terapia e profilaxia de doenças que são com base na interação entre os receptores de vitronectina e seus ligandos nos processos de interação de célula-célula ou célula-matriz ou que podem ser evitadas, amenizadas ou curadas mediante a influência de tais interações. Por exemplo, eles podem ser aplicados para inibir reabsorção óssea pelos osteoclastos e, dessa forma, para tratar e prevenir osteoporose, ou para inibir angiogênese indesejada ou proliferação de células da musculatura lisa vascular. Além disso, a invenção diz respeito aos processos para a preparação de compostos da fórmula I, seu uso, em particular como ingredientes ativos em farmacêuticos, e composições farmacêuticas compreendendo-os.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99112636A EP1065207A1 (en) | 1999-07-02 | 1999-07-02 | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
PCT/EP2000/005920 WO2001002398A1 (en) | 1999-07-02 | 2000-06-26 | Naphthyridine derivatives, processes for their preparation, their use and pharmaceutical compositions comprising them |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0012129A true BR0012129A (pt) | 2002-05-07 |
Family
ID=8238482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0012129-0A BR0012129A (pt) | 1999-07-02 | 2000-06-26 | Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os |
Country Status (33)
Country | Link |
---|---|
US (2) | US6743800B1 (pt) |
EP (2) | EP1065207A1 (pt) |
JP (1) | JP2003503496A (pt) |
KR (1) | KR20020015996A (pt) |
CN (1) | CN1160356C (pt) |
AR (1) | AR024622A1 (pt) |
AT (1) | ATE305471T1 (pt) |
AU (1) | AU775386B2 (pt) |
BG (1) | BG106257A (pt) |
BR (1) | BR0012129A (pt) |
CA (1) | CA2376668C (pt) |
CZ (1) | CZ20014605A3 (pt) |
DE (2) | DE60022890T4 (pt) |
DK (1) | DK1210348T3 (pt) |
EA (1) | EA004369B1 (pt) |
EE (1) | EE200100711A (pt) |
ES (1) | ES2250157T3 (pt) |
HK (1) | HK1050003B (pt) |
HR (1) | HRP20010946A2 (pt) |
HU (1) | HUP0203539A3 (pt) |
IL (1) | IL147248A0 (pt) |
MX (1) | MXPA01013435A (pt) |
MY (1) | MY133246A (pt) |
NO (1) | NO20016404L (pt) |
NZ (1) | NZ516058A (pt) |
PL (1) | PL352280A1 (pt) |
SK (1) | SK19132001A3 (pt) |
TR (1) | TR200103856T2 (pt) |
TW (1) | TW593319B (pt) |
UA (1) | UA73133C2 (pt) |
WO (1) | WO2001002398A1 (pt) |
YU (1) | YU92201A (pt) |
ZA (1) | ZA200200016B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
DE10042655A1 (de) | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
JP4866610B2 (ja) * | 2003-08-18 | 2012-02-01 | 富士フイルムファインケミカルズ株式会社 | ピリジルテトラヒドロピリジン類およびピリジルピペリジン類 |
FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
US20110237605A1 (en) | 2010-03-26 | 2011-09-29 | Eric Phillips | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative |
CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
PT3929196T (pt) | 2013-09-24 | 2023-09-11 | Fujifilm Corp | Composição farmacêutica de um novo composto contendo azoto ou seu sal, ou seu complexo de metal |
AU2021267373A1 (en) | 2020-05-06 | 2022-12-08 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
WO2022140527A1 (en) | 2020-12-23 | 2022-06-30 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
EP4430042A1 (en) | 2021-11-09 | 2024-09-18 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2190870A1 (en) * | 1994-05-27 | 1995-12-07 | George D. Hartman | Compounds for inhibiting osteoclast-mediated bone resorption |
WO1998008940A1 (en) | 1996-08-26 | 1998-03-05 | Novo Nordisk A/S | A novel endoglucanase |
AU724191B2 (en) * | 1996-08-29 | 2000-09-14 | Merck & Co., Inc. | Integrin antagonists |
EP0946164A4 (en) * | 1996-10-30 | 2000-08-23 | Merck & Co Inc | INTEGRIN ANTAGONISTS |
DE19653646A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
CA2277273C (en) * | 1997-01-17 | 2008-03-25 | Merck & Co., Inc. | Integrin antagonists |
EP0933367A1 (en) * | 1997-12-19 | 1999-08-04 | Hoechst Marion Roussel Deutschland GmbH | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists |
SK10632000A3 (sk) * | 1998-01-23 | 2001-02-12 | Aventis Pharma Deutschland Gmbh | Sulfónamidové deriváty ako inhibítory resorpcie kostí a inhibítory bunkovej adhézie |
PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6365589B1 (en) * | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
DE10042655A1 (de) * | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
WO2003059289A2 (en) * | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
JP2008047614A (ja) | 2006-08-11 | 2008-02-28 | Showa Shell Sekiyu Kk | 吸着材を利用した改良型太陽電池モジュール |
-
1999
- 1999-07-02 EP EP99112636A patent/EP1065207A1/en not_active Withdrawn
-
2000
- 2000-06-26 DK DK00945825T patent/DK1210348T3/da active
- 2000-06-26 MX MXPA01013435A patent/MXPA01013435A/es active IP Right Grant
- 2000-06-26 US US10/030,301 patent/US6743800B1/en not_active Expired - Fee Related
- 2000-06-26 AT AT00945825T patent/ATE305471T1/de not_active IP Right Cessation
- 2000-06-26 CN CNB008123365A patent/CN1160356C/zh not_active Expired - Fee Related
- 2000-06-26 TR TR2001/03856T patent/TR200103856T2/xx unknown
- 2000-06-26 CA CA002376668A patent/CA2376668C/en not_active Expired - Fee Related
- 2000-06-26 EP EP00945825A patent/EP1210348B9/en not_active Expired - Lifetime
- 2000-06-26 PL PL00352280A patent/PL352280A1/xx not_active Application Discontinuation
- 2000-06-26 YU YU92201A patent/YU92201A/sh unknown
- 2000-06-26 EA EA200200122A patent/EA004369B1/ru not_active IP Right Cessation
- 2000-06-26 KR KR1020017016961A patent/KR20020015996A/ko not_active Application Discontinuation
- 2000-06-26 SK SK1913-2001A patent/SK19132001A3/sk unknown
- 2000-06-26 JP JP2001507835A patent/JP2003503496A/ja not_active Withdrawn
- 2000-06-26 CZ CZ20014605A patent/CZ20014605A3/cs unknown
- 2000-06-26 DE DE60022890T patent/DE60022890T4/de not_active Expired - Lifetime
- 2000-06-26 EE EEP200100711A patent/EE200100711A/xx unknown
- 2000-06-26 HU HU0203539A patent/HUP0203539A3/hu unknown
- 2000-06-26 DE DE60022890A patent/DE60022890D1/de not_active Expired - Fee Related
- 2000-06-26 NZ NZ516058A patent/NZ516058A/xx unknown
- 2000-06-26 WO PCT/EP2000/005920 patent/WO2001002398A1/en not_active Application Discontinuation
- 2000-06-26 BR BR0012129-0A patent/BR0012129A/pt not_active IP Right Cessation
- 2000-06-26 IL IL14724800A patent/IL147248A0/xx unknown
- 2000-06-26 ES ES00945825T patent/ES2250157T3/es not_active Expired - Lifetime
- 2000-06-26 AU AU59787/00A patent/AU775386B2/en not_active Ceased
- 2000-06-26 UA UA2002020852A patent/UA73133C2/uk unknown
- 2000-06-29 MY MYPI20002962 patent/MY133246A/en unknown
- 2000-06-29 AR ARP000103313A patent/AR024622A1/es active IP Right Grant
- 2000-09-01 TW TW089117925A patent/TW593319B/zh not_active IP Right Cessation
-
2001
- 2001-12-20 BG BG106257A patent/BG106257A/bg unknown
- 2001-12-21 HR HR20010946A patent/HRP20010946A2/hr not_active Application Discontinuation
- 2001-12-28 NO NO20016404A patent/NO20016404L/no not_active Application Discontinuation
-
2002
- 2002-01-02 ZA ZA200200016A patent/ZA200200016B/en unknown
-
2003
- 2003-03-25 HK HK03102163.4A patent/HK1050003B/zh not_active IP Right Cessation
-
2004
- 2004-03-24 US US10/808,496 patent/US20040198718A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY122269A (en) | Novel acylguanidine derivatives as inhibitors of bone resorption and as vitronection receptor antagonists | |
van Beek et al. | Structural requirements for bisphosphonate actions in vitro | |
BR9706387A (pt) | Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos | |
BR9907735A (pt) | Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular | |
BR0012129A (pt) | Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os | |
BR0213562A (pt) | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna | |
BR9916980A (pt) | Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos | |
MX9504630A (es) | Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
NO20051102L (no) | Sulfonylamino-eddiksyre-derivater | |
BRPI0313942B8 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
BR0110767A (pt) | Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina | |
CA2371789A1 (en) | Novel guanidine derivatives as inhibitors of cell adhesion | |
BR9909253A (pt) | Derivados de 2-ariletil-(piperidin-4-ilmetil) amina como antagonistas de receptor muscarìnico | |
BR0012050A (pt) | Derivados de purina substituìda como inibidores da adesão celular | |
BRPI0512420A (pt) | novos derivados de piperidina como moduladores do receptor de quimocina ccr5 | |
BR0207981A (pt) | Derivados de imidazolidina, sua preparação, e seu uso como agente antiinflamatório | |
MXPA02006250A (es) | Derivados de butino diol. | |
ATE360018T1 (de) | Thienylalaninderivate als inhibitoren der zelladhäsion | |
AR023989A1 (es) | DERIVADOS DE ESPIROIMIDAZOLIDINA, SU PROCESO DE PREPARACIoN , LAS COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU UTILIZACIoN PARA LA PREPARACIoN DE UN MEDICAMENTO. | |
DE60138893D1 (pt) | ||
BR0107179A (pt) | Amidinas cìclicas e acìclicas e composições farmacêuticas contendo as mesmas para uso como agentes de ligação de receptor de progesterona | |
MX9601659A (es) | Antagonistas del receptor de adhesion, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades. | |
UA88002C2 (ru) | Производной пиперидина как модуляторы рецептора ccr5 хемокина, способ их получения и фармацевтическая композиция на их основе |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |